Clinical Trials on Multiple Endocrine Neoplasia Type 2A

Total 58811 results

National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
University of Calgary

Recruiting

Hydroxychloroquine and Indapamide in SPMS

Multiple Sclerosis, Secondary Progressive

Canada
Novartis Pharmaceuticals

Completed

Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo

Secondary Progressive Multiple Sclerosis

Australia
Sanofi

Active, not recruiting

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Secondary Progressive Multiple Sclerosis

United States, Argentina, Belgium, Canada, Czechia, France, Germany, Greece, India, Israel, Netherlands, Norway, Portugal, Turkey, United Kingdom, Japan, Austria, Bulgaria, China, Denmark, Finland, Italy, Lithuania, Poland, Romania, Russian... and more
University of Nottingham
Nottingham University Hospitals NHS Trust

Completed

Acceptance Based Telephone Support When Transitioning to SPMS (AT-SPMS)

Secondary Progressive Multiple Sclerosis

United Kingdom
University College, London
University of Leeds; University of Sheffield; Medical Research Council; Queen Mary... and other collaborators

Completed

MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART)

Secondary Progressive Multiple Sclerosis

United Kingdom
Isfahan University of Medical Sciences

Completed

Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients

Secondary Progressive Multiple Sclerosis

Iran, Islamic Republic of
Biogen

Terminated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)

Secondary Progressive Multiple Sclerosis

United States, Finland, Italy, Spain, Canada, France, Israel, Sweden, Netherlands, Belgium, Poland, United Kingdom, Czechia, Denmark, Russian Federation, Germany, Ireland
Eli Lilly and Company
BioMS Technology Corp.

Terminated

A Study for Patients With Multiple Sclerosis (MAESTRO-02)

Secondary Progressive Multiple Sclerosis

Canada, Estonia, Denmark, Finland, Latvia, Spain, Sweden, United Kingdom, Germany, Netherlands
Eli Lilly and Company
BioMS Technology Corp.

Completed

A Study for Patients With Secondary Progressive Multiple Sclerosis (MAESTRO-01)

Secondary Progressive Multiple Sclerosis

Canada, Estonia, Denmark, Finland, Germany, Latvia, Netherlands, Spain, Sweden, United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating Mitoxantrone in Multiple Sclerosis

Secondary Progressive Multiple Sclerosis

Germany
AbbVie

Terminated

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

Exocrine Pancreatic Insufficiency (EPI)

United States
Freeman-Sheldon Research Group, Inc.

Terminated

Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome (STOP-FSS)

Craniofacial Abnormalities | Arthrogryposis | Freeman-Sheldon Syndrome | Arthrogryposis Distal Type 2A | Whistling Face Syndrome | Craniocarpotarsal Dysplasia | Craniocarpotarsal Dystrophy | Freeman-Sheldon Syndrome Variant | Sheldon-Hall Syndrome | Arthrogryposis Distal Type 2B | Gordon Syndrome | Arthrogryposis... and other conditions

United States
Tehran University of Medical Sciences

Completed

Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis (MS)

Multiple Sclerosis | Mesenchymal Stem Cells | Secondary-Progressive Multiple Sclerosis

Iran, Islamic Republic of
National Cancer Institute (NCI)

Active, not recruiting

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Terminated

Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Southwest Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
University Hospital, Montpellier

Terminated

Self-management of Type 1 Diabetes Under Functional Insulin Therapy (EVAUTODIAB)

Type 1 Diabetes | Basal-bolus Multiple-dily Insulin Injections | Insulin Pump (CSII)

France
Innate Immunotherapeutics
Syneos Health

Completed

Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis

Secondary Progressive Multiple Sclerosis

New Zealand, Australia
Biogen

Terminated

BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis (INSPIRE)

Multiple Sclerosis, Secondary Progressive

United States, Poland, Belgium, Slovakia, Czech Republic, Netherlands
Biogen

Withdrawn

Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)

Secondary Progressive Multiple Sclerosis
University College London Hospitals

Completed

A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis

Secondary Progressive Multiple Sclerosis

United Kingdom
Memorial Sloan Kettering Cancer Center
HealthTree Foundation

Recruiting

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM)

Multiple Myeloma, Smoldering

United States
Regeneron Pharmaceuticals

Recruiting

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Smoldering Multiple Myeloma (SMM)

Spain
Omar Nadeem, MD
Janssen, LP

Recruiting

DARA RVD For High Risk SMM (PRISM)

Multiple Myeloma | High-risk Smoldering Multiple Myeloma

United States
Icahn School of Medicine at Mount Sinai
Pharmacyclics LLC.

Terminated

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

High Risk Smoldering Multiple Myeloma

United States
University of Arkansas
Millennium Pharmaceuticals, Inc.

Completed

UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma

Asymptomatic Multiple Myeloma

United States
Masonic Cancer Center, University of Minnesota

Terminated

CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Germ Cell Tumor

United States
Kyverna Therapeutics

Not yet recruiting

A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Multiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive
University of Utah

Completed

Novel Imaging Markers in SPMS

Multiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Secondary Progressive Multiple Sclerosis

United States
Northern Care Alliance NHS Foundation Trust
Brighter AB

Completed

Actiste® Diabetes Management as a Service (ADMS) Clinical Investigation (ADMSUK01)

Diabetes type1 | Diabetes type2

United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy (ITASIA)

Active Secondary Progressive Multiple Sclerosis

Italy
Novartis Pharmaceuticals

Terminated

Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study (SWISSMASIA)

Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity

Switzerland
National Cancer Institute (NCI)

Recruiting

18F-Fluciclovine PET/CT in Multiple Myeloma

Multiple Myeloma | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Newly Diagnosed Multiple Myeloma (NDMM)

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Plasmacytoma | Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
Peng Liu
Shanghai East Hospital; Hrain Biotechnology

Unknown

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Medical College and Hospital Kolkata
Sir Ganga Ram Hospital

Completed

An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms

Pancreatic Endocrine Neoplasms

Clinical Trials on Multiple Endocrine Neoplasia Type 2A

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations